×

US FDA proposes to withdraw approval for Salerno’s cholesterol medication

By Thomson Reuters Nov 17, 2026 | 8:21 AM

Nov 17 (Reuters) – The US Food and Drug Administration’s drug evaluation department is proposing ​to withdraw approval for ‌Salerno Pharmaceuticals’ liquid cholesterol medication, a Federal Register notice showed on Tuesday.

Here are more details:

• The ‌basis ​for the proposal ⁠is that Salerno ⁠has repeatedly failed to file required annual reports for the drug FloLipid, and has not ​responded to the agency’s request for submission of ⁠the reports, the ⁠notice said

• Companies with ​an approved drug for human use ​are required to submit annual ‌reports to FDA concerning their approved new drug application

• The company will be provided ⁠an opportunity for a hearing to show why the approval for the ⁠drug ‌should not be withdrawn

• ⁠FloLipid, a blood cholesterol ​lowering ‌medication, has been formulated ​to ⁠provide an effective liquid-form alternative for those who have difficulty swallowing pills

(Reporting by Sneha S K in Bengaluru; Editing by ​Shailesh Kuber)